This article was originally published in Pharmaceutical Approvals Monthly
Company is discontinuing its diphtheria, tetanus and acellular pertussis vaccine Acel-Imune. Wyeth made the decision after reviewing its product portfolio, production capabilities and the recent consent decree with FDA over violations of good manufacturing practices. Acel-Imune was manufactured at one of the two facilities affected by the consent decree. Acel-Imune and its tetanus toxoids "generated minimal revenue and income," the company said. Sales for the combination were $71 mil. in 2000. Acel-Imune was the leading DTaP vaccine with a 45% share of the $86.3 mil. market for the 12-month period ended in November, according to IMS Health dat
You may also be interested in...
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.